Information DT-061 (SMAP) DT-061 (SMAP) is a bioavailable PP2A activator. It decreases cell viability in HCC827 and HCC3255 cell lines, with IC50 values of 14.3 μM and 12.4 μM respectively. Targets PP2A In vivo PP2A reactivation using single agent SMAP DT-061 is a well-tolerated and orally bioavailable therapeutic strategy that is as efficacious as a combination of kinase inhibitors in antagonizing EGFR-driven TKI-resistant LUAD models. Furthermore, treatment with SMAP can overcome resistance in those models, with an even greater effect when combined with afatinib. Cell Research(from reference) Cell lines：HCC827 and H3255 cell lines Concentrations：2.5, 5, 7.5, 10, 12.5, 15, 17.5, or 20 μM Incubation Time：48 h